Online Inquiry

Plasmid-DNA Therapy Development

DNA molecules can be manipulated to express multiple genes of interest, which can be used for gene therapy applications or vaccine development. Meanwhile, plasmid-DNA therapy shows promising results in the treatment of rare diseases. With extensive experience in rare disease therapy research and development, our company is dedicated to providing clients with plasmid-DNA therapy for rare disease development services.

Introduction to Plasmid-DNA

Natural plasmids are circular DNA molecules that can replicate independently of the chromosome and can be transferred between different bacterial cells. Their use in molecular cloning involves recombining a target gene segment into a plasmid, creating a recombinant gene or recombinant plasmid. This recombinant plasmid is then introduced into recipient cells through microbiological transformation techniques, allowing the target gene within the recombinant plasmid to be stably expressed in the recipient cells, thereby altering the host cell's original characteristics or producing new substances.

2-1-3-1-1 Plasmid-DNA Therapy Development-1Fig.1 Delivery Methods for Plasmids in Cancer Therapeutics. (Martínez-Puente, D. H., et al., 2022)

Plasmid-DNA Therapy for Rare Diseases

Rare diseases have multiple treatment methods, and one promising approach is the use of deoxyribonucleic acid (DNA) molecules for gene therapy. Plasmids are the most commonly used DNA vectors for rare disease treatment and DNA vaccines. When plasmids are taken up by cells, they enter the cell nucleus, and the DNA carried by the plasmid is transcribed to produce mRNA, which further leads to the formation of therapeutic proteins. Compared to other nucleic acid platforms, plasmid DNA used for gene therapy has advantages such as ease of design and manufacturing, low production costs, high stability for transportation and long-term storage, and more.

Table 1 Rare disease plasmid-DNA therapy products currently waiting for approval. (Arabi, F., et al., 2022)

Targets Drug name Indications Details
H19 BC-819 Bladder cancer A recombinant DNA plasmid that directs the expression of a potent toxin specifically in malignant cells
HGF VM202 Painful diabetic peripheral neuropathy A plasmid DNA encoding two isoforms of hepatocyte growth factor (HGF)

Our Services

Based on advanced technology and a professional team, our company provides customers with plasmid-DNA therapy development services, through DNA editing and modification to treat related rare diseases, and provides safe, economical, one-stop gene therapy solutions to accelerate your rare disease research.

Plasmid-DNA Construction

  • Plasmid-DNA element/structure design
  • Recombinant plasmid-DNA construction
  • Plasmid-DNA modification
  • Plasmid-DNA optimization

Plasmid-DNA Analysis

  • Target gene expression analysis
  • Plasmid-DNA sequencing

Plasmid-DNA Delivery

  • Electroporation
  • Ultrasound

Our company provides different expression plasmids for rare disease therapy research and development:

Independent Expression Plasmid Co-Expression Plasmid Fusion Protein Expression Plasmid
Promoter/ Linker Each gene has an individual promoter Two or more genes controlled by the same promoter A linker sequence between both sequences may be added
Codon Optimization
  • Increasing guanine and cytosine to enrich the messenger RNA (mRNA) levels
  • Increasing unmethylated cytosine-phosphate-guanine (CpG) motifs and double-stranded structures stimulate the immune system
Plasmid-DNA Encoded Proteins
  • Therapeutic protein
  • Pro-apoptotic protein
  • An enzyme that activates prodrugs
  • Cytotoxic peptide
  • Antigen or cytokine that stimulates immune cells

Why Choose Us?

With a research team with extensive expertise, our company is confident to provide clients with plasmid-DNA therapy development services for rare diseases. We have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Martínez-Puente, D. H., et al. "Plasmid DNA for therapeutic applications in cancer." Pharmaceutics 14.9 (2022): 1861.
  • Arabi, F., et al. "Gene therapy clinical trials, where do we go? An overview." Biomedicine & Pharmacotherapy 153 (2022): 113324.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.